Shuttle Pharmaceuticals Holdings, Inc. disclosed preliminary estimated unaudited financial results for the year ended December 31, 2025, showing expected net loss between $10.9 million and $12.1 million, revenue of $0, and working capital deficit of $0.7 million to $0.8 million, compared to net loss of $9.1 million in 2024.
Key takeaways
Preliminary net loss for year ended December 31, 2025: $10,862,448 low to $12,083,466 high vs. $9,144,797 actual in 2024
R&D expenses expected $3.4M-$3.9M vs. $3.6M in 2024; anticipated decrease in activities
G&A expenses expected $5.2M-$5.8M vs. $1.4M in 2024, due to $3.6M investor relations advertising
Legal and professional expenses expected $2.1M-$2.3M vs. $2.7M in 2024
Current assets as of Dec 31, 2025: $0.5M vs. $2.2M in 2024; working capital deficit $0.7M-$0.8M vs. $0.7M surplus
Intangible assets, net $9.8M from Molecule.ai asset acquisition; contingent consideration $2.0M, consideration payable $4.4M
All notes payable and convertible notes settled or converted to $0 by Dec 31, 2025